zumilokibart
What stands out
- Injection every 12 or 24 weeks in trials
- Same target as Adbry and Ebglyss, but dosed less often
- Binds to IL-13, a signal molecule that plays a role in allergic inflammation
Derived from FDA substance registry · NCT07003425 · NCT06395948 · UniProt P35225 · · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Apr 29, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- May 14, 2025Phase 2 trial startedA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis ClinicalTrials.gov NCT07003425
- Apr 29, 2024Phase 2 trial startedA Study Evaluating APG777 in Atopic Dermatitis ClinicalTrials.gov NCT06395948
Sources
- Trials